Datavault AI Inc. (NASDAQ: DVLT) has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding its existing technology license with the company, according to a press release. The proposed transaction would allow Datavault AI to retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing. The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions. The proposed expanded license would build on DataMEDS’ existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. The initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI. The letter of intent does not obligate either party to complete the transaction.
The announcement matters because it represents a strategic move by Datavault AI to monetize its intellectual property without bearing the full cost of commercialization, while gaining a board seat and potential upside from DataMEDS’ growth. For DataMEDS, the expanded license could accelerate its health care technology offerings by integrating Datavault AI’s patient-controlled health data solutions. The deal also highlights the growing convergence of AI, blockchain and health care data, where patient-controlled access and tokenization are becoming key differentiators. If completed, the transaction could set a precedent for similar licensing-for-equity arrangements in the tech and health care sectors.
Datavault AI, headquartered in Philadelphia, is known for its AI-driven data experiences and monetization platforms. The company’s Acoustic Sciences division features WiSA, ADIO and Sumerian patented technologies, while its Data Sciences division leverages Web 3.0 and high-performance computing for data perception, valuation and secure monetization. The company’s Information Data Exchange enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. More information about Datavault AI is available at https://dvlt.ai.
The full press release can be viewed at https://ibn.fm/Q8IGK. The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
DefenseWireNews, a specialized communications platform focused on defense contractors, aerospace firms, cybersecurity leaders and advanced manufacturing innovators, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and a full array of tailored corporate communications solutions. For more information, visit DefenseWireNews. Please see full terms of use and disclaimers on the DefenseWireNews website applicable to all content provided by DWN, wherever published or re-published: https://www.DefenseWireNews.com/Disclaimer.
